Phase I/II Trial of Durvalumab Plus Tremelimumab and Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Jan 16

PMID 30642290

Citations 27

Authors

Houda Bahig

Francine Aubin

John Stagg

Olguta Gologan

Olivier Ballivy

Eric Bissada

Felix-Phuc Nguyen-Tan

Denis Soulieres

Louis Guertin

Edith Filion

Apostolos Christopoulos

Louise Lambert

Mustapha Tehfe

Tareck Ayad

Danielle Charpentier

Rahima Jamal

Philip Wong

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy of immunotherapy targeting the PD-1/PD-L1 pathway has previously been demonstrated in metastatic head and neck squamous cell carcinoma (HNSCC). Stereotactic Body Radiotherapy (SBRT) aims at ablating metastatic lesions and may play a synergistic role with immunotherapy. The purpose of this study is to assess the safety and efficacy of triple treatment combination (TTC) consisting of the administration of durvalumab and tremelimumab in combination with SBRT in metastatic HNSCC.

Method: This is a phase I/II single arm study that will include 35 patients with 2-10 extracranial metastatic lesions. Patients will receive durvalumab (1500 mg IV every 4 weeks (Q4W)) and tremelimumab (75 mg IV Q4W for a total of 4 doses) until progression, unacceptable toxicity or patient withdrawal. SBRT to 2-5 metastases will be administered between cycles 2 and 3 of immunotherapy. The safety of the treatment combination will be evaluated through assessment of TTC-related toxicities, defined as grade 3-5 toxicities based on Common Terminology Criteria for Adverse Events (v 4.03), occurring within 6 weeks from SBRT start, and that are definitely, probably or possibly related to the combination of all treatments. We hypothesize that dual targeting of PD-L1 and CTLA-4 pathways combined with SBRT will lead to < 35% grade 3-5 acute toxicities related to TTC. Progression free survival (PFS) will be the primary endpoint of the phase II portion of this study and will be assessed with radiological exams every 8 weeks using the RECIST version 1.1 criteria.

Discussion: The combination of synergistic dual checkpoints inhibition along with ablative radiation may significantly potentiate the local and systemic disease control. This study constitutes the first clinical trial combining effects of SBRT with dual checkpoint blockade with durvalumab and tremelimumab in the treatment of metastatic HNSCC. If positive, this study would lead to a phase III trial testing this treatment combination against standard of care in metastatic HNSCC.

Trial Registration: NCT03283605 . Registration date: September 14, 2017; version 1.

Citing Articles

Survival analysis of patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed radiotherapy and immunotherapy.

Xu P, Liu D, Zhou J, Tang Z, Wang S, Huang Y Radiat Oncol. 2025; 20(1):31.

PMID: 40050916 PMC: 11887223. DOI: 10.1186/s13014-025-02610-1.

The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer.

Sharon S, Daher-Ghanem N, Zaid D, Gough M, Kravchenko-Balasha N Front Oral Health. 2023; 4:1180869.

PMID: 37496754 PMC: 10366623. DOI: 10.3389/froh.2023.1180869.

Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages.

Dong H, Li M, Yang C, Wei W, He X, Cheng G Cancer Cell Int. 2023; 23(1):1.

PMID: 36604694 PMC: 9814316. DOI: 10.1186/s12935-022-02846-x.

Top Ten Lessons Learned from Trials in Oligometastatic Cancers.

Tan V, Palma D Cancer Res Treat. 2022; 55(1):5-14.

PMID: 36567069 PMC: 9873316. DOI: 10.4143/crt.2022.1460.

Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma.

Ng S, Dawson L Biomedicines. 2022; 10(12).

PMID: 36551971 PMC: 9775272. DOI: 10.3390/biomedicines10123215.

References

Lock M, Muinuddin A, Kocha W, Dinniwell R, Rodrigues G, DSouza D . Abscopal Effects: Case Report and Emerging Opportunities. Cureus. 2015; 7(10):e344. PMC: 4641721. DOI: 10.7759/cureus.344. View

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

Leon X, Quer M, Orus C, Venegas M, Lopez M . Distant metastases in head and neck cancer patients who achieved loco-regional control. Head Neck. 2000; 22(7):680-6. DOI: 10.1002/1097-0347(200010)22:7<680::aid-hed7>3.0.co;2-j. View

Demaria S, Kawashima N, Yang A, Devitt M, Babb J, Allison J . Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005; 11(2 Pt 1):728-34. View

Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S . Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-27. DOI: 10.1056/NEJMoa0802656. View

Gibson M, Li Y, Murphy B, Hussain M, DeConti R, Ensley J . Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23(15):3562-7. DOI: 10.1200/JCO.2005.01.057. View

Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum R . Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014; 124(2):687-95. PMC: 3904601. DOI: 10.1172/JCI67313. View

Chow L, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M . Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016; 34(32):3838-3845. PMC: 6804896. DOI: 10.1200/JCO.2016.68.1478. View

Sahgal A, Roberge D, Schellenberg D, Purdie T, Swaminath A, Pantarotto J . The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. Clin Oncol (R Coll Radiol). 2012; 24(9):629-39. DOI: 10.1016/j.clon.2012.04.006. View

10.

Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A . Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One. 2015; 10(6):e0130142. PMC: 4472786. DOI: 10.1371/journal.pone.0130142. View

11.

Benderli Cihan Y . Stereotactic Body Radiation Therapy for Treatment of Spinal Bone Metastasis. Asian Pac J Cancer Prev. 2016; 17(3):937-8. DOI: 10.7314/apjcp.2016.17.3.937. View

12.

Ngwa W, Irabor O, Schoenfeld J, Hesser J, Demaria S, Formenti S . Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018; 18(5):313-322. PMC: 5912991. DOI: 10.1038/nrc.2018.6. View

13.

Onishi H, Kuriyama K, Komiyama T, Tanaka S, Sano N, Marino K . Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner. Lung Cancer. 2004; 45(1):45-55. DOI: 10.1016/j.lungcan.2004.01.004. View

14.

Golden E, Frances D, Pellicciotta I, Demaria S, Barcellos-Hoff M, Formenti S . Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014; 3:e28518. PMC: 4106151. DOI: 10.4161/onci.28518. View

15.

Leemans C, Tiwari R, Nauta J, van der Waal I, Snow G . Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer. 1993; 71(2):452-6. DOI: 10.1002/1097-0142(19930115)71:2<452::aid-cncr2820710228>3.0.co;2-b. View

16.

Hellman S, Weichselbaum R . Oligometastases. J Clin Oncol. 1995; 13(1):8-10. DOI: 10.1200/JCO.1995.13.1.8. View

17.

Wu C, Yang L, Yang H, Knoff J, Peng S, Lin Y . Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res. 2013; 20(3):644-57. PMC: 3946442. DOI: 10.1158/1078-0432.CCR-13-1334. View

18.

Concha-Benavente F, Srivastava R, Trivedi S, Lei Y, Chandran U, Seethala R . Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res. 2015; 76(5):1031-43. PMC: 4775348. DOI: 10.1158/0008-5472.CAN-15-2001. View

19.

Nyman J, Johansson K, Hulten U . Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients. Lung Cancer. 2005; 51(1):97-103. DOI: 10.1016/j.lungcan.2005.08.011. View

20.

Lo S, Fakiris A, Chang E, Mayr N, Wang J, Papiez L . Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2009; 7(1):44-54. DOI: 10.1038/nrclinonc.2009.188. View